Skip to Content
Stock Analyst Update

The Week in Stocks: Expedia Makes a Thrilling Offer

...That Shareholders Should Refuse.

Mentioned: , , , , , , , , ,

On Friday, Expedia (EXPE) unveiled plans to buy back up to 10% of its shares outstanding through a tender offer. Morningstar analyst Sumit Desai is thrilled to see the company put its nearly $1 billion cash hoard to use. Desai also points out that the company indicated that its directors and officers and Liberty Media (LINTA) do not intend to tender any of their shares. In Desai's opinion, this decision to forgo the tender offer reflects management's belief that Expedia has a brighter future ahead of itself. Desai agrees, as the stock continues to trade at a considerable discount to his fair value estimate. For that reason, he recommends that current shareholders follow management's lead by holding on to their shares, as the tender offer price still does not fully reflect the company's intrinsic worth. Desai is maintaining his fair value estimate for now, but could raise it by a few dollars depending on how many shares are actually tendered.
 Full Analyst Report: Expedia

Novartis Sells Part of Consumer Unit
On Thursday, Novartis (NVS) announced that it was selling its medical nutrition business to Nestle (NSRGY) for $2.5 billion. In reviewing the deal, Morningstar analyst Heather Brilliant points out that the medical nutrition unit--which includes nutritional products and medical devices used to provide sustenance to patients who are typically unable to consume adequate nutrition on their own--is a small part of Novartis' overall consumer health business. As such, the sale should have no material impact on her fair value estimate. Separately, Novartis also announced that the FDA had extended its review of the company's Tekturna hypertension drug. Novartis provided additional data on the drug in early December, so the FDA probably intends to take extra time to incorporate that new data into Novartis' application. This announcement also does not affect Brilliant's fair value estimate, as she had not expected Tekturna to reach the market until 2008, a timetable she thinks is still achievable. 
 Full Analyst Report: Novartis AG

Jeffrey Ptak has a position in the following securities mentioned above: NVS, WU. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.